Literature DB >> 20947517

Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.

Laura Mosca1, Sonia Fabris, Marta Lionetti, Katia Todoerti, Luca Agnelli, Fortunato Morabito, Giovanna Cutrona, Adrian Andronache, Serena Matis, Francesco Ferrari, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio Lambertenghi Deliliers, Silvio Bicciato, Manlio Ferrarini, Antonino Neri.   

Abstract

PURPOSE: Chromosome 13q14 deletion occurs in a substantial number of chronic lymphocytic leukemia (CLL) patients and it is believed to play a pathogenetic role. The exact mechanisms involved in this lesion have not yet been fully elucidated because of its heterogeneity and the imprecise knowledge of the implicated genes. This study was addressed to further contribute to the molecular definition of this lesion in CLL. EXPERIMENTAL
DESIGN: We applied single-nucleotide polymorphism (SNP)-array technology and gene expression profiling data to investigate the 13q14 deletion occurring in a panel of 100 untreated, early-stage (Binet A) patients representative of the major genetics, molecular, and biological features of the disease.
RESULTS: Concordantly with FISH analysis, SNP arrays identified 44 patients with del(13)(q14) including 11 cases with a biallelic deletion. The shorter monoallelic deletion was 635-kb long. The loss of the miR-15a/16-1 cluster occurred in all del(13)(q14) cases except in 2 patients with a monoallelic deletion, who retained both copies. MiR-15a/16 expression was significantly downregulated only in patients with the biallelic loss of the miRNA cluster compared to 13q normal cases. Finally, the natural grouping of SNP profiles by nonnegative matrix factorization algorithm showed that patients could be classified into 2 separate clusters, mainly characterized by short/biallelic versus wide/monoallelic 13q14 deletions. Supervised analyses of expression data showed that specific transcriptional profiles are correlated with these 2 genomic subgroups.
CONCLUSIONS: Overall, our data highlight the presence of 2 distinct molecular types of 13q14 deletions, which may be of clinical relevance in CLL. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947517     DOI: 10.1158/1078-0432.CCR-10-0151

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; Megan Hanna; Bethany Tesar; Lillian Werner; Nathalie Pochet; John M Asara; Yaoyu E Wang; Paola Dal Cin; Stacey M Fernandes; Christina Thompson; Laura Macconaill; Catherine J Wu; Yves Van de Peer; Mick Correll; Aviv Regev; Donna Neuberg; Arnold S Freedman
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

3.  Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Authors:  Rebeqa Gunnarsson; Larry Mansouri; Anders Isaksson; Hanna Göransson; Nicola Cahill; Mattias Jansson; Markus Rasmussen; Jeanette Lundin; Stefan Norin; Anne Mette Buhl; Karin Ekström Smedby; Henrik Hjalgrim; Karin Karlsson; Jesper Jurlander; Christian Geisler; Gunnar Juliusson; Richard Rosenquist
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

4.  Identification of functional cooperative mutations of SETD2 in human acute leukemia.

Authors:  Xiaofan Zhu; Fuhong He; Huimin Zeng; Shaoping Ling; Aili Chen; Yaqin Wang; Xiaomei Yan; Wei Wei; Yakun Pang; Hui Cheng; Chunlan Hua; Yue Zhang; Xuejing Yang; Xin Lu; Lihua Cao; Lingtong Hao; Lili Dong; Wei Zou; Jun Wu; Xia Li; Si Zheng; Jin Yan; Jing Zhou; Lixia Zhang; Shuangli Mi; Xiaojuan Wang; Li Zhang; Yao Zou; Yumei Chen; Zhe Geng; Jianmin Wang; Jianfeng Zhou; Xin Liu; Jianxiang Wang; Weiping Yuan; Gang Huang; Tao Cheng; Qian-Fei Wang
Journal:  Nat Genet       Date:  2014-02-09       Impact factor: 38.330

5.  Combined somatic mutation and copy number analysis in the survival of familial CLL.

Authors:  Weiyin Zhou; Lynn Goldin; Mingyi Wang; Mary L McMaster; Kristine Jones; Laurie Burdett; Stephen J Chanock; Meredith Yeager; Michael Dean; Neil E Caporaso
Journal:  Br J Haematol       Date:  2018-04-24       Impact factor: 6.998

6.  Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy.

Authors:  G Cutrona; S Matis; M Colombo; C Massucco; G Baio; F Valdora; L Emionite; S Fabris; A G Recchia; M Gentile; C E Neumaier; D Reverberi; R Massara; S Boccardo; L Basso; S Salvi; F Rosa; M Cilli; S Zupo; M Truini; P Tassone; M Calabrese; M Negrini; A Neri; F Morabito; F Fais; M Ferrarini
Journal:  Leukemia       Date:  2017-01-05       Impact factor: 11.528

7.  The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia.

Authors:  Peter Ouillette; Roxane Collins; Sajid Shakhan; Jinghui Li; Cheng Li; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2011-09-02       Impact factor: 12.531

8.  Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.

Authors:  Jane Houldsworth; Asha Guttapalli; Venkata Thodima; Xiao Jie Yan; Geetu Mendiratta; Tania Zielonka; Gouri Nanjangud; Weiyi Chen; Sujata Patil; Anthony Mato; Jennifer R Brown; Kanti Rai; Nicholas Chiorazzi; R S K Chaganti
Journal:  Leuk Lymphoma       Date:  2013-11-12

Review 9.  The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia.

Authors:  S N Malek
Journal:  Oncogene       Date:  2012-09-24       Impact factor: 9.867

10.  Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Daphne R Friedman; Joseph E Lucas; J Brice Weinberg
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.